New clinical data indicates that a major form of medication has a massive impact on a prominent virus.
AbbVie’s late-stage information demonstrates that the ribavirin-free hepatitis C therapy glecaprevir/pibrentasvir has achieved high cure rates across the majority of patients infected with the virus.
Glecaprevir/pibrentasvir is a once-daily regimen that combines two distinct antiviral agents.
Both the NS3/4A protease inhibitor glecaprevir (300mg) and NS5A inhibitor pibrentasvir (120mg)... Readmore
The National Institute for Health and Care Excellence (NICE) has backed the utilisation of Novartis’ Cosentyx (secukinumab) in adults with active and progressive psoriatic arthritis.
Progressive psoriatic arthritis is an inflammatory disease that affects joints and connective-tissue, impacting over 117,000 people in Britain.
It can strike at any point during a person's lifetime, but the most affected the group are those aged between 40 and 50.
The watchdog is already recommending the use of Cosentyx... Readmore
The pharmaceutical company Allergan has announced a major collaboration with Novartis.
This new arrangement between the pharma giants will see them test a new combination therapy approach for non-alcoholic steatohepatitis.
Non-alcoholic steatohepatitis is a progressive form of non-alcoholic fatty liver disease that is considered to be the fastest growing cause of liver cancer and liver transplant in the United States.
In order to achieve this, Allergan is expanding its research and development... Readmore
Onzima Ventures has announced the conditional acquisition of the remaining 51% of the issued shares of N4 Pharma Limited, effectively taking over the firm.
Consideration for the acquisition will be satisfied by the issue of 4,510,800 New Ordinary Shares and 4,591,400 Deferred Consideration Shares.
The Company has also conditionally raised £1.5 million (gross) by way of a placing of 21,428,571 New Ordinary Shares at 7p per share .
This will be utilised in order to fund development of additional... Readmore
Polyphor Ltd has the completion of a CHF40 million private placement.
Exisiting Polyphor investors contributed to 98% of the financing.
Polyphor is a clinical stage, privately held Swiss specialty pharma company focused on the development of macrocycle drugs addressing antibiotic resistance and respiratory diseases.
The proceeds will be used to finance the Pharma business unit, and particularly the pivotal registration programme of the antibiotic Murepavadin (POL7080) against... Readmore
A breast cancer drug that has previously been withdrawn in England has been made available via the NHS in Scotland.
This is the second blow for medical prescriptions south of the border, after NHS Scotland agreed to fund PrEP for HIV sufferers.
Kadcyla is used to treat the form of breast cancer known as HER2 positive.
The Scottish Medicines Consortium (SMC) suggest that making the major available to patients in Scotland will enable them to spend "more time with their families and in some... Readmore
PrEP is to be made available in Scotland, with AIDS campaigners suggesting that the English authorities should now follow suit.
Two major court rulings have previously forbade this process, but it is hoped that the authorities will now make the medicine available for HIV sufferers in other British nations.
The Scottish Medicines Consortium (SMC) decided to make PrEP free on the NHS to those who could require the drug.
Access to the medication could begin within the next few weeks.
A new study widely reported in the British media suggests that taking antibiotics for in excess of two weeks can massively increase the risk of bowel cancer developing.
However, reports on the matter have been rather misleading, as the study in question did not in fact assess the level of bowel cancer.
What it did discover is an increased risk of bowel polyps for women who took antibiotics for two months or more.
The study was carried out by researchers from Harvard Medical School, Harvard... Readmore
New resources are being made available to employers, training providers and employment professionals to help alleviate London’s social care skills shortages.
Ambition London, funded by JP Morgan Chase Foundation, has authored two new toolkits.
These are intended to promote skills-sharing and tackle common misconceptions of careers in both the health and social care sectors.
It is known that health and adult social care sectors face an acute shortage of skilled workers with too few entrants,... Readmore
A poll of major firms suggests that European countries will be prioritised over Britain after NHS bosses decided that expensive drugs should be delayed.
Leading pharmaceutical firms also believe that cancer drugs will be most strongly affected by the changes that have been instigated by the National Institute for Health and Care Excellence and NHS England.
The new survey of 32 members of the Association of the British Pharmaceutical Industry (ABPI) found that 71% believe their companies will... Readmore
Researchers in Denmark have suggested that the painkiller ibuprofen can increase the risk of cardiac arrest occurring.
This has lead to calls for the sale of the drug to be limited.
The new study suggests that taking ibuprofen on a regular basis can increase the risk of cardiac arrest by 31%.
Findings published in the European Heart Journal also suggest that other painkillers from the same non-steroidal anti-inflammatory drugs (NSAIDs) can present an even higher risk.
Diclofenac, available... Readmore
Health chiefs have announced a massive drugs cap with the intention of saving money for the English healthcare system.
A £20 million figure will be set in an attempt to ensure that NHS England reduces its financial deficit.
While the cuts will have fiscal benefits for the NHS, experts are already concerned about the implications for the availability of medicine.
It is already suggested that this new initiative could lead to delays of up to three years before new drugs are available to NHS patients.